Ipca Laboratories Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Ipca Laboratories şirketinin kazançları yıllık ortalama -9.6% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 13.4% oranında artan oldu. Gelirler yıllık ortalama 11.7% oranında artan oldu. Ipca Laboratories şirketinin öz sermaye getirisi 8.2% olup, net marjı 7.7% dir.

Anahtar bilgiler

-9.6%

Kazanç büyüme oranı

-9.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	17.5%
Gelir büyüme oranı	11.7%
Özkaynak getirisi	8.2%
Net Marj	7.7%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07

Recent updates

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Nov 17

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Sep 10

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Sep 20

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Aug 09

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Jun 08

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Mar 26

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Mar 13

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Feb 28

Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Feb 23

Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Feb 11

Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Jan 30

The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It

Jan 15

Gelir ve Gider Dağılımı

Ipca Laboratories nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NSEI:IPCALAB Gelir, gider ve kazançlar (INR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	85,343	6,612	19,464	0
30 Jun 24	82,133	5,768	18,624	0
31 Mar 24	77,059	5,474	17,321	0
31 Dec 23	71,875	5,643	15,923	0
30 Sep 23	66,806	4,922	14,517	0
30 Jun 23	62,500	4,911	13,450	0
31 Mar 23	62,481	4,713	13,102	0
31 Dec 22	60,225	5,250	12,779	0
30 Sep 22	59,070	6,142	12,431	0
30 Jun 22	58,505	7,205	12,204	0
31 Mar 22	58,305	8,841	11,972	0
31 Dec 21	56,561	9,152	11,555	0
30 Sep 21	56,355	9,837	11,169	0
30 Jun 21	54,521	10,005	10,751	0
31 Mar 21	54,207	11,400	10,318	0
31 Dec 20	53,802	10,647	10,135	0
30 Sep 20	51,833	9,968	9,997	0
30 Jun 20	51,061	9,228	9,772	0
31 Mar 20	46,499	6,063	9,366	0
31 Dec 19	44,563	6,189	8,911	0
30 Sep 19	42,496	5,804	8,455	0
30 Jun 19	39,777	5,059	8,254	0
31 Mar 19	37,750	4,448	8,123	0
31 Mar 18	32,852	2,394	7,604	0
31 Mar 17	31,562	1,945	7,182	0
31 Mar 16	28,671	931	6,474	0
31 Mar 15	31,444	2,542	5,872	0
31 Mar 14	32,818	4,785	9,200	852

Kaliteli Kazançlar: IPCALAB yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: IPCALAB 'nin mevcut net kar marjları (7.7%) geçen yılın (7.4%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: IPCALAB şirketinin kazançları son 5 yılda yılda 9.6% oranında azaldı.

Büyüme Hızlandırma: IPCALAB 'un son bir yıldaki kazanç büyümesi ( 34.3% ) 5 yıllık ortalamasını (yıllık -9.6% ) aşıyor.

Kazançlar vs. Sektör: IPCALAB geçen yılki kazanç büyümesi ( 34.3% ) Pharmaceuticals sektörünün 20% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: IPCALAB 'nin Özsermaye Getirisi ( 8.2% ) düşük olarak değerlendiriliyor.

Ipca Laboratories Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Ipca Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024

Ipca Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Full year 2024 earnings released: EPS: ₹25.82 (vs ₹18.58 in FY 2023)

Recent updates

Second quarter 2025 earnings: EPS in line with analyst expectations despite revenue beat

Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00

Dividend of ₹2.00 announced

Ipca Laboratories Limited to Report Q2, 2025 Results on Nov 14, 2024

Ipca Laboratories Limited Announces Cessation of Manisha Premnath as Independent Director and Member of the Nomination & Remuneration Committee and Stakeholders Relationship Committee, Effective September 21, 2024

Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)

Price target increased by 8.6% to ₹1,320

Ipca Laboratories Limited Approves Appointment of Vivek Shiralkar as an Independent Director

Upcoming dividend of ₹2.00 per share

Ipca Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Less than half of directors are independent

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Ipca Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Full year 2024 earnings released: EPS: ₹25.82 (vs ₹18.58 in FY 2023)

Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

Ipca Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director

Price target increased by 9.1% to ₹1,097

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Ipca Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

CFO, MD & Executive Director recently sold ₹22m worth of stock

Price target increased by 9.7% to ₹987

Upcoming dividend of ₹2.00 per share at 0.2% yield

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023

Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Ipca Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q4, 2023 Results on May 29, 2023

Price target decreased by 7.1% to ₹858

Investor sentiment deteriorates as stock falls 15%

Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Consensus EPS estimates fall by 21%

Third quarter 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million.

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on December 7, 2022

Ipca Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Insider recently sold ₹1.7m worth of stock

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Ipca Laboratories Limited Approves Interim Dividend as Final Dividend for Financial Year Ended 31St March, 2022

Now 20% undervalued

Ipca Laboratories Limited Announced Demise of Dev Parkash Yadava, Non-Executive and Independent Director

Ipca Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Now 20% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2022

Now 20% undervalued after recent price drop

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Now 20% undervalued after recent price drop

Price target decreased to ₹1,067

Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Full year 2022 earnings: EPS misses analyst expectations

Insufficient new directors

CFO, Joint MD & Executive Director recently sold ₹21m worth of stock

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?